The key catalyst is the NXT-41 FDA clearance decision expected in Q4 2026 and the NXT-41x FDA submission in the same quarter. Monitor for FDA decisions and any Cardiovascular business transaction, which could extend the cash runway further.
Drug in focus
ELUT drug pipeline →NXT-41
▲ Bullish Named in this 8-K- Impact
- Phase
- Filed/510(k) submission
- Time to market
- NXT-41 (base matrix) clearance decision expected Q4 2026 (within ~2 months). NXT-41x (antibiotic-eluting) clearance expected Q2 2027, with first full year of commercial launch targeted for 2028.
- Next catalyst
- None dated
What to watchWatch for the FDA 510(k) clearance decision on NXT-41 (base biologic matrix), expected by end of Q4 2026 (any day now through December). A clearance would validate the platform and clear the path for NXT-41x submission. The bigger catalyst is NXT-41x clearance expected Q2 2027, which would open the $1.5B breast reconstruction market. The company is fully funded through launch, removing near-term dilution risk. However, as a micro-cap single-product story, any regulatory delay or negative FDA feedback would hit the stock hard.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $0.8374entry
- T+1 · 8d ago −0.18%α −2.55% · $0.8359
- T+5 · 4d ago −2.08%α −4.67% · $0.8200
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Elutia reported Q3 2026 net sales of $1.1M (+20.4% YoY) but a net loss from continuing operations of $6.5M, significantly wider than the $1.0M loss a year ago, driven by higher R&D spending on NXT-41x. The company secured $26M in non-dilutive capital, completed the SimpliDerm sale, and is on track to submit NXT-41x to the FDA in Q4 2026, with cash runway through the first full year of commercialization.
Key Financial Metrics
Key Facts
- Q3 2026 net sales from continuing operations were $1.1M, up 20.4% from $0.9M in Q3 2025.
- Net loss from continuing operations was $6.5M, compared to a $1.0M loss in Q3 2025.
- Adjusted EBITDA loss was $5.6M, compared to a $3.4M loss in the prior year period.
- Cash and cash equivalents at September 30, 2026 were $29.1M; an additional $8M escrow release received on October 1, 2026.
- Elutia added $26M in capital without an equity offering via the SimpliDerm sale ($8M), Boston Scientific escrow release ($8M), and Avenue Capital loan ($10M funded, $5M available post-clearance).
- NXT-41x GLP rabbit study met prespecified endpoints, with no viable bacteria recovered after MRSA and E. coli challenges.
- NXT-41 FDA clearance decision anticipated in Q4 2026; NXT-41x FDA submission planned for Q4 2026.
- Cardiovascular revenue grew 20% YoY to $1.1M in Q3 2026; adjusted gross margin of 85.5%.
- GAAP gross margin improved to 61.7% from 52.8%; adjusted gross margin was 85.5% from 81.3%.
- Total operating expenses were $7.6M, up from $6.4M, driven by a $1.9M increase in R&D.
Financial Impact
Q3 2026 continuing ops net sales $1.1M; net loss from continuing ops $6.5M; cash $29.1M; $26M raised in non-dilutive capital
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cardiovascular | $1.1M | +20.4% |
Risk Factors
- NXT-41 and NXT-41x may not receive FDA clearance on the anticipated timeline or at all.
- The company is pre-revenue for its lead pipeline program and continues to generate significant operating losses.
- Dependence on a limited number of third-party suppliers, including Cook Biotech as sole supplier for Cardiovascular products.
- FiberCel and VBM litigation remains a contingent liability, though the balance has been reduced.
- The company must maintain compliance with Nasdaq listing requirements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-123316 |
| Document: elut-20261105x8k.htm | 0001104659-26-123316 |
| Document: 0001104659-26-123316-index-headers.html | 0001104659-26-123316 |
| Document: 0001104659-26-123316-index.html | 0001104659-26-123316 |
| Document: 0001104659-26-123316.txt | 0001104659-26-123316 |
| 8-K Data (Synthetic) | 0001104659-26-123316 |
Track record
7 reports on ELUT
Filters
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
- Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
- Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
- May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
- Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers